MY-943 是一种有效的 tubulin polymerization 和 LSD1 抑制剂,具有抗癌活性,可诱导 G2/M 期阻滞和细胞凋亡、抑制细胞迁移,可用于胃癌的研究。
产品编号: MS-C02502 纯度: 98.01% CAS No.: 3043676-46-3 分子式: C30H36N4O6S2 分子量: 612.76
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价

产品描述

MY-943 是一种有效的 tubulin polymerization 和 LSD1 抑制剂,具有抗癌活性,可诱导 G2/M 期阻滞和细胞凋亡、抑制细胞迁移,可用于胃癌的研究。

生物实验数据

生物活性 MY-943 is a potent tubulin polymerization and LSD1 inhibitor with anticancer activity that induces G2/M phase arrest and apoptosis, inhibits cell migration, and can be used for gastric cancer research.
体外研究
(In Vitro)

MY-943 对三种癌细胞具有抗增殖活性,MGC-803 细胞的 IC50 值为 0.019 μM,HCT-116 细胞为 0.044 μM,KYSE450 细胞为 0.030 μM。
MY-943(10, 20, 30 nM; 20, 40, 48, 60 h)剂量依赖性和时间依赖性抑制 MGC-803 和 SGC-7901 细胞的细胞活力。
MY-943(1, 5, 10 μM; 48 h)剂量依赖性地减弱 EBI 存在下 β-微管蛋白的烷基化作用,并防止 MGC-803 和 SGC-7901 细胞中 β-微管蛋白:EBI 加合物带的形成。
MY-943(10, 20, 30 nM; 8, 16, 24 nM; 48 h)浓度依赖性地抑制 MGC-803 和 SGC-7901 细胞中的微管蛋白聚合。
MY-943(10, 20, 30 nM; 8, 16, 24 nM; 48 h)剂量依赖性诱导细胞凋亡。
MY-943 以剂量依赖性方式下调 Bcl-2 和 Mcl-1(抗凋亡蛋白)的表达水平,并以剂量依赖性方式增加裂解的 Caspase-3 和 Caspase-7 的表达水平。 MY-943(10, 20, 30 nM; 8, 16, 24 nM; 48 h)剂量依赖性下调 Weel、CyclinB1 和 CDC2 的表达水平,并剂量依赖性地增加 p-组蛋白 H3,H3K4me1 和 H3K4me2 的表达水平。
MY-943(10, 20, 30 nM; 8, 16, 24 nM; 48 h)有效且剂量依赖性地诱导 G2/M 期停滞。
MY-943(10, 20, 30 nM; 8, 16, 24 nM; 48 h)显著抑制胃癌细胞MGC-803和SGC-7901的迁移能力。

Cell Viability Assay

Cell Line: MGC-803 and SGC-7901 cells
Concentration: 10, 20, 30 nM
Incubation Time: 20, 40, 48, 60 h
Result: Dose-dependently inhibited the cell viability of MGC-803 and SGC-7901 cells (10, 20, 30 nM; 48 h). Time-dependently inhibited the cell viability of MGC-803 and SGC-7901 cells (10, 20, 30 nM; 20, 40, 60 h).

Western Blot Analysis

Cell Line: MGC-803 and SGC-7901 cells
Concentration: 1, 5, 10 μM
Incubation Time: 48 h
Result: Dose-dependently weakened the alkylation of β-tubulin in the presence of EBI, and prevented the formation of β-tubulin:EBI adduct band in MGC-803 and SGC-7901 cells.

Immunofluorescence

Cell Line: MGC-803 and SGC-7901 cells
Concentration: 10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells
Incubation Time: 48 h
Result: Concentration-dependently inhibited tubulin polymerization in MGC-803 and SGC-7901 cells, thereby destroying the microtubule network.

Immunofluorescence

Cell Line: MGC-803 and SGC-7901 cells
Concentration: 10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells
Incubation Time: 48 h
Result: A concentration-dependently made cell nuclei brighten, shrink, and vary in size, and when the concentration was 24 nM for MGC-803 cells or 30 nM for SGC-7901 cells, the nucleus appeared broken, showing the morphological characteristics of apoptotic cells and the proportion of dead cells increased.

Cell Proliferation Assay

Cell Line: MGC-803 and SGC-7901 cells
Concentration: 10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells
Incubation Time: 48 h
Result: Effectively and dose-dependently induced G2/M phase arrest. After the treatment with 24 nmol/L (MGC-803 cells) or 30 nmol/L (SGC-7901 cells), the percentages of G2/M phase in MGC-803 and SGC-7901 cells were 60% and 74%. While the percentages of G2/M in untreated groups were 33% (MGC-803 cells) and 32% (SGC-7901 cells), respectively.

Western Blot Analysis

Cell Line: MGC-803 and SGC-7901 cells
Concentration: 10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells
Incubation Time: 48 h
Result: Down-regulated the expression levels of Bcl-2 and Mcl-1 (anti-apoptotic proteins) in a dose-dependent manner, significantly increased the protein levels of cleaved Caspase-3 and Caspase-7.

Western Blot Analysis

Cell Line: MGC-803 and SGC-7901 cells
Concentration: 10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells
Incubation Time: 48 h
Result: Down-regulated the expression levels of the proliferation related proteins Weel and CDC2 in dose-dependent manners, thus leading to the decrease of cdc2 phosphorylation (thr161). While decreased the expression level of CyclinB1 (a G2 phase related protein), and obviously increased the expression level of p-Histone H3 (a M phase marker protein) in a dose-dependent manner.

Western Blot Analysis

Cell Line: MGC-803 and SGC-7901 cells
Concentration: 10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells
Incubation Time: 48 h
Result: With the increase of concentrations, increased the expression levels of H3K4me1 and H3K4me2, indicating that inhibited cellular activity of LSD1 in MGC-803 and SGC-7901 cells.

Cell Migration Assay

Cell Line: MGC-803 and SGC-7901 cells
Concentration: 10, 20, 30 nM for SGC-7901 cells; 8, 16, 24 nM for MGC-803 cells
Incubation Time: 48 h
Result: Exhibited significant inhibitory effects on the migratory ability of gastric cancer cells MGC-803 and SGC-7901 cells.
体内研究
(In Vivo)

MY-943(25 mg/kg/天;腹腔注射;21 天)显著抑制小鼠胃癌的生长,并大大降低小鼠肿瘤组织的重量和体积。

Animal Model: BALB/c-nu nude mice
Dosage: 25 mg/kg
Administration: 25 mg/kg/day; i.p.; 21 days
Result: Significantly inhibited the growth of gastric cancer and greatly reduced the weight and volume of the tumor tissues.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 612.76
分子式 C30H36N4O6S2
CAS No. 3043676-46-3

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (163.20 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.6320 mL8.1598 mL16.3196 mL40.7990 mL
5 mM0.3264 mL1.6320 mL3.2639 mL8.1598 mL
10 mM0.1632 mL0.8160 mL1.6320 mL4.0799 mL
15 mM0.1088 mL0.5440 mL1.0880 mL2.7199 mL
20 mM0.0816 mL0.4080 mL0.8160 mL2.0400 mL
25 mM0.0653 mL0.3264 mL0.6528 mL1.6320 mL
30 mM0.0544 mL0.2720 mL0.5440 mL1.3600 mL
40 mM0.0408 mL0.2040 mL0.4080 mL1.0200 mL
50 mM0.0326 mL0.1632 mL0.3264 mL0.8160 mL
60 mM0.0272 mL0.1360 mL0.2720 mL0.6800 mL
80 mM0.0204 mL0.1020 mL0.2040 mL0.5100 mL
100 mM0.0163 mL0.0816 mL0.1632 mL0.4080 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础